Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
Rhea-AI Summary
Prenetics (NASDAQ: PRE), parent of health and longevity brand IM8, appointed Brian J. Rosin as U.S. Chief Financial Officer on May 14, 2026. He will lead finance, capital allocation, investor relations support, and financial infrastructure, reporting to CEO Danny Yeung.
Rosin brings nearly 20 years of experience in consumer e-commerce and premium wellness subscriptions. IM8 is active in 40+ countries and is projecting $190–$210 million in 2026 revenue, its second year from launch.
Positive
- IM8 projects $190–$210 million in 2026 revenue in year two
- IM8 products now sold in more than 40 countries
- Appointment of experienced CFO establishes dedicated IM8 finance leadership
- Nearly 20 years of relevant consumer wellness and e-commerce experience added
Negative
- None.
News Market Reaction – PRE
In the May 14 session, PRE gained 0.11%, reflecting a mild positive market reaction. Argus tracked a trough of -16.5% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Earnings call timing | Neutral | +1.8% | Announcement of Q1 2026 results date and earnings conference call details. |
| May 07 | Sports partnership | Positive | -0.2% | IM8 named exclusive health supplements partner of Inter Miami CF with equity stake. |
| Apr 28 | Dividend declaration | Positive | -5.3% | First Horizon declared cash dividends on common and preferred stock. |
| Apr 14 | Impact partnership | Positive | -0.9% | IM8 Health and Vitamin Angels partnered to address global malnutrition at scale. |
| Apr 02 | Celebrity partnership | Positive | +0.6% | Giannis Antetokounmpo became IM8 Global Partner and shareholder in multi-year deal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent IM8-related partnership and branding announcements often coincided with flat-to-negative next-day moves, suggesting the stock has not consistently rewarded positive brand news in the short term.
Over the past months, Prenetics highlighted IM8’s rapid scaling and brand-building. On Apr 2, a multi-year partnership with Giannis Antetokounmpo underscored IM8’s $100M ARR milestone and a strong liquidity position, with a modest positive price reaction. Subsequent partnerships, including the Vitamin Angels collaboration and Inter Miami CF deal, emphasized global reach and projected 2026 revenue growth but saw muted or negative reactions. The latest CFO appointment fits this theme of building IM8’s infrastructure for global expansion.
Key Terms
direct-to-consumer financial
private equity-backed financial
e-Commerce financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced the appointment of Brian J. Rosin as U.S. Chief Financial Officer. Mr. Rosin will be based in the U.S. and will lead the Company's finance organization, reporting to Chief Executive Officer Danny Yeung. Mr. Rosin's appointment establishes dedicated finance leadership for IM8 to support the Company's growing operations and the rapid global expansion of the IM8 brand.
Mr. Rosin brings nearly two decades of financial leadership in consumer e-Commerce and premium wellness subscription brands, with significant transaction experience including several successful exits. He joins Prenetics at a pivotal moment, as IM8 has become one of the fastest growing supplement brands ever recorded in the industry, is now sold in more than 40 countries, and is projecting
In his new role, Mr. Rosin will be responsible for financial strategy, capital allocation, investor relations support, and the financial infrastructure and unit-economics discipline required to scale a premium consumer health brand from breakout launch to durable, profitable, global category leadership.
Danny Yeung, Co-Founder and Chief Executive Officer of Prenetics, commented: "Brian’s entire career has been spent at the intersection of high growth consumer, premium nutrition, and subscription supplements in e-Commerce. He understands the unit economics, brand-building discipline, and operating cadence required to turn a breakout consumer health product into an enduring, global category leader. As IM8 expands across more than 40 countries and into new daily nutrition formats, Brian's expertise will be invaluable in ensuring the financial discipline and infrastructure behind our growth match the ambition of the brand."
Brian J. Rosin, Chief Financial Officer of IM8, commented: "I've spent nearly two decades helping build premium consumer health brands, and what drew me to IM8 was the data — the unit economics and retention here are unlike anything I've seen in the category. David Beckham as a co-founding partner, world-class athletes as authentic users, science-backed formulations, and an AI-native operating culture make for a rare platform in consumer health. I'm honored to join Danny and the team, and I look forward to building the financial foundation to support IM8's next phase of growth in the United States and globally."
Mr. Rosin joins Prenetics from Wellbeam Consumer Health, a private equity-backed e-Commerce-focused consumer wellness platform, where he served as Chief Financial Officer and Senior Vice President, e-Commerce Operations. In those roles, he led finance and digital commerce across Wellbeam's portfolio of brands, including TruSkin (clean, plant-powered skincare), BioTRUST Nutrition (direct-to-consumer nutrition for healthy aging), Eu Natural (women's botanical supplements), and Penetrex (joint and muscle therapy, divested in 2024). He originally joined TruSkin as CFO in 2020, prior to its acquisition by Wellbeam in 2021. Earlier in his career, he also held CFO roles at NATURELO Premium Supplements, and Rant, Inc. Mr. Rosin holds dual bachelor's degrees, Cum Laude, in Economics and Political Science from Northern Illinois University.
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is trusted by NBA Champion and two-time MVP Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka, and F1 driver Ollie Bearman. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company's flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing
Investor Relations Contact:
investors@prenetics.com | PRE@mzgroup.us
Angela Cheung Investor Relations / Corporate Finance angela.hm.cheung@prenetics.com
